Key points are not available for this paper at this time.
The etiology of Alzheimer's disease (AD) has been extensively studied for a long time, primarily associated with multifaceted mechanisms involving aggregation of amyloid beta, tau hyperphosphorylation, neuroinflammation, and immune regulation. Current therapeutics for AD are significantly targets to attenuate the cognitive decline by modulating neurotransmitters and diminishing aggregation of amyloid beta. However, these therapeutics fail to address the neuroimmune dysregulation that critically facilitates disease progressions. In this study, we have delineated the phytochemical potential to modulate the amyloid beta-triggered immune regulation through in silico approaches. Seventy three phytochemicals were selected from established anti-Alzheimer's plants through literature mining and sequentially administrated to pharmacodynamic and pharmacokinetic investigations. The draggable study has established 14 phytochemicals, and the compounds were further curated based on their molecular interactions with the hub-targets, enriched in the amyloid beta-driven immune regulation. AD-associated proteins were retrieved from different data sets such as GeneCards, DisGeNet, GEO, and Opentargets, and the intersecting targets were curated for downstream analysis. Functional annotation and network pharmacology analysis mapped APOE4, BACE1, TREM2, IL-1β, and TNF-α as key regulatory targets. The molecular interaction analysis revealed that genkwanin and kaempferol exhibited strong binding affinity and stable interactions with the hub-targets as a potent candidates to attenuate the immune regulation in AD. Further molecular mechanics/Poisson-Boltzmannsson-Boltzmann surface area and DFT analysis have revealed their thermodynamic stability and electronic reactivity, highlighting their potential efficacy in mitigating AD progression.
Kalidass et al. (Fri,) studied this question.